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Chronic pulmonary colonisation with Pseudomonas aeruginosa (PA) in patients with CF is associated with a high morbidity and
mortality. Adequate treatment of first acquisition of PA might prevent or postpone chronic colonisation. Early detection of PA is therefore of
major importance. Currently, cultures of oropharynx or sputum are most commonly practised. However, oropharyngeal culture has
limitations both in the positive and negative predictive value for the presence of PA in the lower respiratory tract. Induction of sputum has
little benefit in detection of PA. Serology might have additional value in early detection, when bacterial density is too low to be detected by
culture. Molecular techniques are not yet widespread used for detection of PA, but have in general a high sensitivity. In this review, we
describe the value of different diagnostic techniques for detecting PA.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Culture; Serology; Antibodies; PCR; Sensitivity; Infection1. Introduction
Cystic fibrosis is an inherited multi-system disease,
caused by a mutation in the CFTR-gene. It is characterised
by dysfunction of the exocrine glands and subsequent
chronic obstruction in lungs and exocrine pancreatic
insufficiency. Chronic obstruction in the lung predisposes
for pulmonary infection. Hyperinflammation by persistent
infiltration of neutrophils in the airways, even in patients
without clinical apparent disease, precedes and accompanies
pulmonary infection [1]. In infants, pulmonary infections
with Staphylococcus aureus and Haemophilus influenzae
are common. Later in childhood, infections with Pseudo-
monas aeruginosa (PA) become dominant. Twenty percent
of 1-year old infants are infected with PA, with an increase
in incidence of about 33% in 3-year olds until 80–90% in
adulthood [2]. Pseudomonal infection is a multi-stage1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.05.009
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enzyme-linked immunosorbent assay; CIE, crossed immune electropho-
resis; PCR, polymerase chain reaction.
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PA to the epithelial lining of the respiratory tract, and may
be transient. If not, aggressive antimicrobial treatment may
eradicate PA in this early stage and postpone chronic
colonisation [3–8]. Eventually, intermittent colonisation
becomes chronic and phenotypes of PA change to alginate
producing antibiotic-resistant strains that form biofilms [9].
Chronic PA infection is associated with deterioration of lung
function and disease progression, mediated by host inflam-
matory, mainly neutrophilic, response [10,11].
Standard method for assessing respiratory infections with
PA is bacterial culture of sputum, oropharyngeal (cough)
swabs or broncho-alveolar lavage fluid (BALF). Culture of
BALF can be defined as the reference standard, because it
reflects colonisation of the lower respiratory tract. However,
BAL is an invasive procedure, and therefore not routinely
performed as a diagnostic screening test. Culturing sputum
or oropharyngeal swabs is currently the most frequently
used method to establish PA carrier status. New identifica-
tion techniques to trace PA like polymerase chain reaction
(PCR) are forthcoming [12–14]. Recently, it was suggested
that serologic parameters convert before a culture shows PA
[11,15,16].s 4 (2005) 37 – 43ed by Elsevier B.V. All rights reserved.
Table 1
Available methods for Pseudomonas aeruginosa screening in cystic fibrosis
patients
Methods Examples
Culture
–Processing
General culture media Blood agar
Gram-negative culture
media
McConkey agar
Selective culture media Pseudomonas isolation agar,
cetrimide agar
–Site
Nasopharynx Nasopharyngeal aspirate
Oropharynx Posterior pharynx/tonsils swab
Cough swab
Bronchi Sputum spontaneously expectorated
Sputum induced by hypertonic saline
Bronchi/Alveoli Broncho-alveolar lavage
(BAL)-aspirate
Antibody tests
Enzyme-linked
immunosorbent
assay (ELISA)
Non-purified antigens, e.g.,
whole cell protein
Purified antigens, e.g.,
exoproteins
Western immunoblot Whole cell protein
Crossed immune
electrophoresis (CIE)
Precipitins
Diverse
Molecular techniques Polymerase chain reaction (PCR)
Fluorescent in situ
hybridisation (FISH)
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serology and molecular techniques for detection of PA
colonisation in patients with CF. Table 1 summarises the
techniques that are available.2. Culture of Pseudomonas aeruginosa from the
respiratory tract
Bacteria in the respiratory tract are most frequently
detected by culture. Conventional qualitative and quanti-
tative culture uses non-selective and selective plate media.Table 2
Diagnostic values of oropharyngeal cultures for Pseudomonas aeruginosa, with B
Author No. of BAL Age Ref. standar
Armstrong, 1996 150 1–52 months BAL PA>1
Rosenfeld, 1999 141 < 60 months BAL PA>1
BAL PA an
119 < 18 month
82 > 18 month
Burns, 2001 108 < 36 months BAL PA an
1 OP cult
2 OP cult (t
Ramsey, 1991 43 4 months–25 years BAL PA an
Ref. standard—reference standard; Sens—sensitivity; Spec—specificity; PPV—pPA is easily cultured on different media. On blood agar, a
non-selective medium, PA sometimes is overgrown by
commensal throat flora. Gram-negative selective media
like McConkey agar makes discrimination of PA from
other respiratory pathogens and indigenous flora more
convenient. Pseudomonas selective plates like PA isolation
agar or cetrimide agar have been developed especially for
culture of PA. Within 48 h, PA can be detected on these
media [13,17].
The culture site plays an important role in detection of
PA. We describe the value of cultures from the upper
respiratory tract and cultures of induced sputum in relation
to culture of BALF or spontaneously expectorated sputum.
2.1. Cultures from the oropharynx
In young children, oropharyngeal (OP) cultures are often
used to identify respiratory pathogens. This also counts for
older patients who are not able to expectorate sputum. The
diagnostic accuracy of OP-culture has important clinical
implications, because it is the only non-invasive way of
assessing respiratory tract pathogens [17]. Table 2 shows
diagnostic and predictive values of OP-cultures compared
with BALF-cultures. In young asymptomatic children, PA
positive OP-cultures do not reliably predict the presence of
bacterial pathogens in the lower airways, however, negative
OP-cultures indicate that PA is unlikely to be present in the
lower airways [11,17,18]. In older children and sympto-
matic patients, there is a higher prevalence of PA with a
concomitant better positive predictive value [17,19,20].
Combining results of more OP-cultures reduces the number
of false negative cultures, and therefore increase negative
predictive value [11]. In patients with PA both cultured from
BALF and oropharynx, Pulsed Field Gel Electrophoresis
(PFGE) showed poor predictive accuracy of OP-isolates for
lower airway organisms [18]. This indicated that actual
positive predictive value might be different.
Fewer data exist on sensitivity of cough swab cultures.
Cough swab cultures showed, in a small group of 30
patients, high positive predictive value but low sensitivity in
comparison with cultures of spontaneously expectorated
sputum [21].ALF-culture as Freference standard_
d Sens% Spec% PPV% NPV%
0.5 cfu/ml 71 93 57 96
0.5 cfu/ml 82 94 64 97
y growth
s 44 95 44 95
s 68 94 76 91
y growth
69 85
= 3 months, t =0) 83 97
y growth 46 93 83 70
ositive predictive value; NPV—negative predictive value.
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lower respiratory tract, as indicated by BALF-culture as a
reference standard, limit oropharyngeal cultures. Non-
invasive PA that harbours only temporary in the pharynx
possibly explains these low positive predictive values.
Errors or differences in sampling technique may also be
responsible for low values, although sampling technique
was extensively evaluated in cited studies. Sensitivities in
Table 2 are to be compared with caution, because different
definitions were used for a positive BALF-culture, and so
definition of the reference standard.
2.2. Cultures of sputum
Simultaneous detection of PA in sputum and BALF
samples is not widely described. In 17 sputum-producing
adult CF patients, BALF showed seven times an extra PA
strain compared with the sputum sample. In two patients,
PA infection was newly diagnosed by BAL [22]. In an older
study, culture of sputum of CF patients showed high
correlation with culture of thoracotomy specimens [23].
Controversy exists whether induction of sputum for
detection of PA is of benefit in children with CF.
Originally developed for measuring inflammatory param-
eters in induced sputum in asthmatic subjects, recently, this
technique has also been used for detection of lower
respiratory tract pathogens in patients with CF [24,25].
Induction of sputum by inhaling nebulized hypertonic
saline is a relatively easy and safe procedure [24,26,27].
Volume of induced sputum is significantly larger than
spontaneous expectorated sputum, also in previous non-
expectorating children [26,28,29]. It is a reliable procedure
as measured by a high reproducibility of inflammatory
markers and respiratory pathogens [28]. Nevertheless, it is
not frequently used in young children, because it can
induce bronchoconstriction.
Table 3 shows results of PA status pre- and post-sputum
induction. In a young patient group with respiratory
symptoms, 32% of 41 patients demonstrated more and/or
other specimens of bacteria after sputum induction [30]. InTable 3
Additional detection of Pseudomonas aeruginosa with sputum induction in
patients with CF
Author Sample
size
Age
(years)
PA pre-
induction
(%)a
PA post-
induction
(%)
Respiratory symptoms
Ho, 2004 41 1.8–12.9 7 7
No symptoms
De Boeck, 2000 15 4.3–15.2 33 47
Sagel, 2001 19 7–12 32 21
Suri, 2003 32 7.3–17 56 59
Henig, 2001 10 19–38 Pa mucoid 60 60
Pa non-mucoid 10 30
a As determined by OP-, nasopharyngeal or sputum-culture.total, this study group had low number of PA positive
patients and only one additional PA was found in induced
sputum. In studies with non-symptomatic patients, slight
differences were found between pre- and post-induced
cultures [24,27,29]. In a small study group, Henig found
high agreement between cultures of spontaneous expecto-
rated sputum, induced sputum and BALF regarding mucoid
PA, while there was less agreement for non-mucoid PA [26].
Consequently, it seems that induction of sputum for
detecting PA has relatively little practical benefit, although
existing data regarding PA positive cultures after sputum
inductions were derived from small study groups. In addition,
most study groups existed of non-symptomatic patients. One
reason for low additional detection might be that PA infection
by itself gives a higher chance of spontaneous sputum
production. Differences in culturing BALF and induced
sputum are less clear. However, in comparison with BAL, it is
a non-invasive and less intensive procedure.3. Detection of Pseudomonas aeruginosa with molecular
techniques
Molecular techniques for detection of PA are still not
universally used. PCR has high sensitivity for detection of
PA in sputum in culture-positive patients. Karpati et al.
demonstrated presence of PA in sputum by PCR-technique
and compared them with cultures. A sensitivity of 93% was
found [31]. Other studies showed sensitivities between 97
and 100%, depending on primers [12,13,32]. For example,
outer membrane protein (oprL) gene locus is more sensitive
than Exotoxin A (ETA) gene locus [14]. Molecular
detection of PA in sputum might be a useful technique in
the early detection of PA. In 10 culture-negative patients
with a positive PCR, culture became positive later in 5
patients in a mean time of 4.5 months [13]. In a different
study, many PCR-positive culture-negative samples were
found. Eighty-three percent of these samples were OP-
samples. A sampling error in OP-cultures or misidentifica-
tion was not ruled out and no follow up was done [12].
FISH is another technique to detect PA. Sensitivity of FISH
in comparison with culture is not very high, since the limit
for microscopic detection depends on high bacterial density
within sputum samples [33].
Advantages of PCR-technique are high sensitivity and
possibility of early detection of respiratory pathogens.
Another benefit of these molecular techniques is that they
can help in establishing cross-infections between patients.4. Detection of antibodies against Pseudomonas
aeruginosa
Infection with PA can be proven both by culturing of the
organism itself and by detection of immune response to the
micro-organism. Antibody testing with ELISA demonstra-
Table 4
Sensitivity of single sample antibody testing for Pseudomonas aeruginosa
Author Sample size Test Sensitivity (%)
Chronic colonisation
Granstrom, 1984 22 ELISA
–Phospholipase C
100
–Exotoxin A 68
–Alkaline
protease
73
–Elastase 23
Hollsing, 1987 26 ELISA
–Phospholipase C
100
–Exotoxin A 58
–Alkaline
protease
58
–Elastase 15
Pedersen, 1987 91 ELISA whole
cell protein
96
108 CIE precipitating
antibodies
100
Intermittent colonisation
Pedersen, 1987 20 CIE precipitating
antibodies
50
Early colonisation with first positive culture
Brett, 1988 33 ELISA whole
cell protein
88
Burns, 2001 18 ELISA exotoxin
A (BAL+)
94
11 (OP only+) 91
Immunoblot whole
cell protein
18 (BAL+) 94
11 (OP only+) 82
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directed against other bacteria [15,34]. Chronic infection in
general elicits a high antibody response; literature suggests
advantages in early infection too [11,16,35]. For the
methods, we refer to Table 1.
4.1. Factors that determine extent of antibody response
The purified antibodies against PA show different trends
in elevation during infection. There is a temporal hierarchy
described in development of antibodies: anti-exotoxin A and
anti-phospholipase C antibodies seem to develop first, time
to titre elevation of anti-elastase and anti-alkaline protease
antibodies is prolonged. In addition, frequencies of elevated
antibodies seem to vary among different antigens
[16,36,37].
There are several factors influencing antibody develop-
ment. Mucoid PA strains induce a more pronounced antibody
response comparing to non-mucoid strains [36,38]. Dual
colonisation with Staphylococcus aureus can be accompa-
nied with lower antibody titres of exotoxin A and elastase, but
with higher titres of phospholipase C [37,39].
Antibody titres rise during periods of active infection.
There is a decrease noted with antimicrobial treatment [37].
Chronically PA infected CF patients who are treated
intensively with antibiotics have lower antibody responses
[7,37,40,41]. Continuous steroid treatment is accompanied
by a decline in antibody titre [15].
Theoretically, other foci of PA infection can induce an
increased antibody titre. These foci of PA infection are, e.g.,
ear or wound infection and cystitis. Not much literature
exists on development of anti-PA antibodies in these
infections. Few patients with PA cystitis, ear or wound
infection showed antibody response, and in general, this
response was lower than the response seen in CF patients
with pulmonary PA infection [42–44].
Most diagnostic antibody tests are based on IgG anti-
bodies. Other serum immunoglobulins, especially IgA, also
show elevation of specific PA antibody titres. Elevation was
particularly seen in patients with pulmonary PA infections,
other foci elicited fewer specific IgA antibodies [34,45–47].
In addition, titre of anti-PA IgA, like anti-PA IgG, correlates
with disease severity and might be a better parameter for
follow-up than anti-PA IgG, because it reflects endobron-
chial infection [45,48].
4.2. Antibody response in chronic Pseudomonas aeruginosa
infection
Patients with chronic PA infection show high (more than 2
standard deviations above those of normal control values)
IgG titres to proteins of PA [35,49]. Sensitivity and specificity
of serology in chronic colonisation differ slightly among
distinct methods and antigens. Table 4 shows sensitivities of
diverse antibody tests. Antibody levels obtained by whole
cell protein ELISA and level of precipitins correlated witheach other and showed both a sensitivity between 96 and
100% for PA colonisation [50]. Instead, ELISAwith a single
purified antigen has a lower sensitivity for confirming
chronic colonisation, and is antigen-dependent [36]. In most
alternative studies, no single antigen was able to detect the
antibody response in all CF patients [37,51].
4.3. Antibody response in intermittent Pseudomonas aeru-
ginosa infection
From longitudinal studies, it is known that elevated
antibody titres are not only observed with chronic infection,
but also in an early stage of infection. Intermittent
colonisation may give rise to formation of specific anti-
bodies. However, lower titres are found in patients with
intermittent colonisation compared with chronic colonisa-
tion [35,50]. As antibody titres are also influenced by
antimicrobial treatment, titres may vary.
4.4. Antibody response in early Pseudomonas aeruginosa
infection
Table 5 describes numbers of patients that have
evidence of anti-PA antibodies without positive culture.
In majority of patients, there is an early antibody response
Table 5
Prevalence of anti-Pseudomonas aeruginosa antibodies in patients who are
culture-negative during study period
Author Sample size Test Percentage
Brett, 1988 33 ELISA whole cell protein 73
Burns, 2001 11 ELISA exotoxin A 36
Immunoblot Whole cell protein 91
West, 2002 16 ELISA –Exotoxin A 69
–Cell lysate 88
–Elastase 44
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studies demonstrate a higher incidence of infection than
cultures do. In a study performed by Burns et al., time of
first detection of antibody for both exotoxin A and whole
cell protein immunoblot preceded the detection of PA by
culture. By 3 years of age, 97.5% of patients showed
evidence of PA infection, measured by a combination of
two serologic assays, BALF- and OP-culture. As deter-
mined by culture only, 72.5% of patients demonstrated
evidence of PA during their first 3 years [11]. Increase of
anti-PA antibodies occurred even 6–12 months before PA
was isolated from cultures of the respiratory tract in
young children. Development of antibodies before iso-
lation of PA occurred in approximately 50–70% of
patients [15,16].
Thus, patients with chronic colonisation have in general a
firm antibody response to PA. Follow-up of serology gives
information about progress of disease and can be useful for
monitoring PA infection. Patients with early infection may
have elevated antibody titres months before a culture
becomes positive. However, not all patients show an early
antibody response. Serological testing in addition to
culturing can be helpful, particularly for symptomatic
patients without positive culture, or patients that have
positive OP-culture without symptoms.5. Conclusion
Early detection of PA in patients with CF is of major
importance because aggressive antimicrobial therapy
might prevent or postpone chronic PA colonisation and
subsequent disease progression. We estimated the value of
different detection methods for clinical practise. Conven-
tional cultures have limitations, especially in site of
culturing and sampling technique. In young children, PA
positive OP-cultures are not good predictors for presence
of PA in the lower airways. Also, a negative OP-culture
does not definitively exclude the presence of PA in the
lower respiratory tract. In older children, positive pre-
dictive value is better. Predictive values of OP-cultures
can be improved by culturing more regularly. Pathogens
in spontaneously expectorated sputum show better con-
cordance with lower respiratory tract pathogens. Sputum
induction in children has little additional value fordetection of PA in comparison with conventional culture
of sputum or oropharynx. Early detection of PA is a
hallmark of serological and molecular techniques. Anti-
bodies against PA may emerge months before a culture
becomes positive, and are a useful parameter for infection
monitoring in PA colonised patients as titres may vary
with antimicrobial treatment. Polymerase Chain Reaction
of sputum or OP-samples demonstrated detection of PA in
CF patients in an early stage too, and has a high
sensitivity for PA colonisation. Additional benefit of PCR
is identifying cross-infections. Serological and molecular
techniques are particularly helpful in early or intermittent
colonisation, because chronic colonisation is often easily
confirmed by culture.Acknowledgements
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